$15.52
Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says
B. Riley Adjusts Price Target on Climb Bio to $30 From $26, Maintains Buy Rating
Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble
Overview
52-week range
$1.54
$18
83% of range
Avg surprise (last 3)
-17.3%
Avg reaction (last 2)
-5.2%
0% positive
Latest IV / EM
109%
EM ±17.1% · $15 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.18 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.20 | $-0.26 | +23.1% | +35.5% | -2.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.19 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.13 | $-0.19 | +31.6% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.31 | $-0.15 | -106.7% | — | -7.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.13 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.81 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.06 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.15 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.19 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.84 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-15M | $-15M | — | $-15M | $-11M | $-23M | — | $-12M |
| Net income | $-13M | $-14M | — | $-13M | $-9M | $-21M | — | $-9M |
| EPS (diluted) | $-0.18 | $-0.20 | — | $-0.19 | $-0.13 | $-0.31 | — | $-0.13 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $44M | $8M | $36M | $26M | $23M | $29M | $87M | $146M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $187M | $113M | $106M | $91M | $87M | $100M | $155M | $198M |
| Total assets | $246M | $152M | $168M | $182M | $192M | $201M | $217M | $222M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $7M | $4M | $7M | $5M | $7M | $7M | $5M | $3M |
| Total equity | $240M | $148M | $160M | $177M | $186M | $193M | $212M | $219M |